Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

THE SCRIPPS RESEARCH INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1924-12-11

Employees: 1K

Market Cap: -

Website: https://powermom.scripps.edu

Clinical Trials

A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases

Phase 1

Not yet recruiting

Conditions: Systemic Lupus Erythematosus (SLE)
Systemic Sclerosis (SSc)
Idiopathic Inflammatory Myopathy (IIM)

First Posted Date: 2025-04-06

Last Posted Date: 2025-04-06

Lead Sponsor: Calibr, a division of Scripps Research

Target Recruit Count: 12

Registration Number: NCT06913608

Long Term Follow-up Study for Subjects Administered CLBR001

Not yet recruiting

Conditions: Long Term Follow-Up

First Posted Date: 2025-03-18

Last Posted Date: 2025-03-18

Lead Sponsor: Calibr, a division of Scripps Research

Target Recruit Count: 40

Registration Number: NCT06882317

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer Metastatic
Locally Advanced Breast Cancer (LABC)
Malignant Neoplasm of Breast
Triple Negative Breast Cancer (TNBC)
Hormone Receptor-Positive Breast Cancer
HER2 + Breast Cancer

Interventions: Biological: Two Component Product CLBR001 + ABBV-461

First Posted Date: 2025-03-14

Last Posted Date: 2025-06-08

Lead Sponsor: Calibr, a division of Scripps Research

Target Recruit Count: 20

Registration Number: NCT06878248

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

Phase 1

Recruiting

Conditions: Pulmonary Fibroses, Idiopathic

Interventions: Drug: CMR316
Drug: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-23

Lead Sponsor: Calibr, a division of Scripps Research

Target Recruit Count: 106

Registration Number: NCT06589219

Locations: 🇩🇪
Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Hannover, Germany

Study to Assess PDM608 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: PDM608
Drug: Placebo

First Posted Date: 2023-07-18

Last Posted Date: 2024-08-06

Lead Sponsor: Calibr, a division of Scripps Research

Target Recruit Count: 64

Registration Number: NCT05950906

Locations: 🇺🇸
Quotient Sciences-Miami, Inc, Miami, Florida, United States

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Phase 1

Conditions: Chronic Lymphocytic Leukemia (CLL)
Mantle Cell Lymphoma (MCL)
Small Lymphocytic Lymphoma (SLL)
Relapsed/Refractory B-cell Lymphomas
Primary Mediastinal Large B Cell Lymphoma
Lymphoplasmacytic Lymphoma
Burkitt Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Follicular Lymphoma (FL)
Marginal Zone Lymphoma (MZL)

Interventions: Combination Product: CLBR001 and SWI019

First Posted Date: 2020-07-28

Last Posted Date: 2025-01-10

Lead Sponsor: Calibr, a division of Scripps Research

Target Recruit Count: 36

Registration Number: NCT04488354

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
University of California at San Diego, San Diego, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 5 locations

Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo

Phase 2

Completed

Conditions: Alcohol Use Disorder

Interventions: Drug: Placebo oral tablet
Drug: Miricorilant

First Posted Date: 2020-07-10

Last Posted Date: 2023-02-03

Lead Sponsor: The Scripps Research Institute

Target Recruit Count: 50

Registration Number: NCT04466215

Locations: 🇺🇸
The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research, La Jolla, California, United States

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma (DLBCL)
Burkitt Lymphoma
Follicular Lymphoma (FL)
Marginal Zone Lymphoma (MZL)
Transformed Follicular Lymphoma
Waldenstrom Macroglobulinemia
Relapsed/Refractory B-cell Lymphomas
Chronic Lymphocytic Leukemia (CLL)
Mantle Cell Lymphoma
Primary Mediastinal Large B Cell Lymphoma

Interventions: Combination Product: CLBR001 and SWI019

First Posted Date: 2020-06-29

Last Posted Date: 2024-08-20

Lead Sponsor: Calibr, a division of Scripps Research

Target Recruit Count: 18

Registration Number: NCT04450069

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
University of California at San Diego, San Diego, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 5 locations

Medication Development in Alcoholism: Suvorexant Versus Placebo

Phase 2

Completed

Conditions: Alcohol Use Disorder (AUD)

Interventions: Drug: Suvorexant 20 mg
Drug: Placebo oral tablet

First Posted Date: 2020-01-14

Last Posted Date: 2023-04-26

Lead Sponsor: The Scripps Research Institute

Target Recruit Count: 26

Registration Number: NCT04229095

Locations: 🇺🇸
Scripps Research, La Jolla, California, United States

MAP4343 Treatment for Alcohol Use Disorder

Phase 2

Withdrawn

Conditions: Alcohol Use Disorder

Interventions: Drug: Placebo
Drug: MAP4343
Behavioral: Standardized behavioral counseling

First Posted Date: 2019-11-08

Last Posted Date: 2022-03-11

Lead Sponsor: The Scripps Research Institute

Registration Number: NCT04157114

Locations: 🇺🇸
The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research, La Jolla, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy